Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab
Gespeichert in:
| Veröffentlicht in: | Blood cancer journal (New York) 2020-09, Vol.10 (9), p.92, Article 92 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 9 |
| container_start_page | 92 |
| container_title | Blood cancer journal (New York) |
| container_volume | 10 |
| creator | Gentile, Massimo Martino, Enrica Antonia Visentin, Andrea Coscia, Marta Reda, Gianluigi Sportoletti, Paolo Mauro, Francesca Romana Laurenti, Luca Varettoni, Marzia Murru, Roberta Chiarenza, Annalisa Vigna, Ernesto Mendicino, Francesco Lucia, Eugenio Bossio, Sabrina Recchia, Anna Grazia Moia, Riccardo Pietrasanta, Daniela Loseto, Giacomo Consoli, Ugo Scortechini, Ilaria Rossi, Francesca Maria Zucchetto, Antonella Al-Janazreh, Hamdi Vitale, Candida Tripepi, Giovanni D’Arrigo, Graziella Angeletti, Ilaria Bomben, Riccardo Neri, Antonino Cutrona, Giovanna Fronza, Gilberto Di Raimondo, Francesco Gaidano, Gianluca Cuneo, Antonio Foà, Robin Ferrarini, Manlio Trentin, Livio Gattei, Valter Morabito, Fortunato |
| description | |
| doi_str_mv | 10.1038/s41408-020-00358-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7494850</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2443879033</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-d0c86c7180cdb97b224996963679b9004be8063ee18f3339d3fc517a174d481f3</originalsourceid><addsrcrecordid>eNp9kcFuFSEUhonR2ObaF-jCkLipi7GHgRlgY2JuWjW5SZNWuyUMMC117nALzLXd-Q6-oU8it7et1YVsIDkf__nP-RHaJ_COABWHiREGooIaKgDaiIo-Q7s1MFY1VDTPn7x30F5KV1BO0xJJ5Eu0Q2tJhQS2i67P9eCtzj6MOPRY4zTFtV_roYo-fcPJhOjwwdnp2VvsRxzdoFfJ2cPo-qhNDvEWzxcLvCoCbswJ5-h0dhZ_9_kSe1vwwSff_frxM_o83fil7l6hF70ektu7v2fo6_HRl_mnanHy8fP8w6IyjLNcWTCiNZwIMLaTvKtrJmUrW9py2UkA1jkBLXWOiJ5SKi3tTUO4JpxZJkhPZ-j9Vnc1dUtnTfEX9aBWsZiItypor_6ujP5SXYS14kwy0UAROLgXiOF6cimrpU_GDYMeXZiSqhmjgkso3WfozT_oVZjiWMbbULWglDdNoeotZWJIqazw0QwBtQlVbUNVJVR1F6raSL9-Osbjl4cIC0C3QCql8cLFP73_I_sb47GuVA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2442833755</pqid></control><display><type>article</type><title>Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Springer Nature OA Free Journals</source><source>Nature Free</source><source>PubMed Central</source><creator>Gentile, Massimo ; Martino, Enrica Antonia ; Visentin, Andrea ; Coscia, Marta ; Reda, Gianluigi ; Sportoletti, Paolo ; Mauro, Francesca Romana ; Laurenti, Luca ; Varettoni, Marzia ; Murru, Roberta ; Chiarenza, Annalisa ; Vigna, Ernesto ; Mendicino, Francesco ; Lucia, Eugenio ; Bossio, Sabrina ; Recchia, Anna Grazia ; Moia, Riccardo ; Pietrasanta, Daniela ; Loseto, Giacomo ; Consoli, Ugo ; Scortechini, Ilaria ; Rossi, Francesca Maria ; Zucchetto, Antonella ; Al-Janazreh, Hamdi ; Vitale, Candida ; Tripepi, Giovanni ; D’Arrigo, Graziella ; Angeletti, Ilaria ; Bomben, Riccardo ; Neri, Antonino ; Cutrona, Giovanna ; Fronza, Gilberto ; Di Raimondo, Francesco ; Gaidano, Gianluca ; Cuneo, Antonio ; Foà, Robin ; Ferrarini, Manlio ; Trentin, Livio ; Gattei, Valter ; Morabito, Fortunato</creator><creatorcontrib>Gentile, Massimo ; Martino, Enrica Antonia ; Visentin, Andrea ; Coscia, Marta ; Reda, Gianluigi ; Sportoletti, Paolo ; Mauro, Francesca Romana ; Laurenti, Luca ; Varettoni, Marzia ; Murru, Roberta ; Chiarenza, Annalisa ; Vigna, Ernesto ; Mendicino, Francesco ; Lucia, Eugenio ; Bossio, Sabrina ; Recchia, Anna Grazia ; Moia, Riccardo ; Pietrasanta, Daniela ; Loseto, Giacomo ; Consoli, Ugo ; Scortechini, Ilaria ; Rossi, Francesca Maria ; Zucchetto, Antonella ; Al-Janazreh, Hamdi ; Vitale, Candida ; Tripepi, Giovanni ; D’Arrigo, Graziella ; Angeletti, Ilaria ; Bomben, Riccardo ; Neri, Antonino ; Cutrona, Giovanna ; Fronza, Gilberto ; Di Raimondo, Francesco ; Gaidano, Gianluca ; Cuneo, Antonio ; Foà, Robin ; Ferrarini, Manlio ; Trentin, Livio ; Gattei, Valter ; Morabito, Fortunato</creatorcontrib><identifier>ISSN: 2044-5385</identifier><identifier>EISSN: 2044-5385</identifier><identifier>DOI: 10.1038/s41408-020-00358-3</identifier><identifier>PMID: 32938904</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/699/1541/1990/283/1895 ; 692/699/1541/1990/291/1621/1915 ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Correspondence ; Disease-Free Survival ; Female ; Hematology ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell - mortality ; Male ; Middle Aged ; Monoclonal antibodies ; Oncology ; Purines - administration & dosage ; Quinazolinones - administration & dosage ; Rituximab - administration & dosage ; Survival Rate ; Targeted cancer therapy</subject><ispartof>Blood cancer journal (New York), 2020-09, Vol.10 (9), p.92, Article 92</ispartof><rights>The Author(s) 2020</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-d0c86c7180cdb97b224996963679b9004be8063ee18f3339d3fc517a174d481f3</citedby><cites>FETCH-LOGICAL-c474t-d0c86c7180cdb97b224996963679b9004be8063ee18f3339d3fc517a174d481f3</cites><orcidid>0000-0001-5933-9680 ; 0000-0001-9047-5912 ; 0000-0002-3335-1101 ; 0000-0002-2592-8724 ; 0000-0003-1222-6149 ; 0000-0003-3722-553X ; 0000-0002-5256-0726 ; 0000-0003-1831-7340 ; 0000-0001-7393-1138 ; 0000-0002-2585-7073</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494850/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494850/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,862,883,27907,27908,41103,42172,51559,53774,53776</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32938904$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gentile, Massimo</creatorcontrib><creatorcontrib>Martino, Enrica Antonia</creatorcontrib><creatorcontrib>Visentin, Andrea</creatorcontrib><creatorcontrib>Coscia, Marta</creatorcontrib><creatorcontrib>Reda, Gianluigi</creatorcontrib><creatorcontrib>Sportoletti, Paolo</creatorcontrib><creatorcontrib>Mauro, Francesca Romana</creatorcontrib><creatorcontrib>Laurenti, Luca</creatorcontrib><creatorcontrib>Varettoni, Marzia</creatorcontrib><creatorcontrib>Murru, Roberta</creatorcontrib><creatorcontrib>Chiarenza, Annalisa</creatorcontrib><creatorcontrib>Vigna, Ernesto</creatorcontrib><creatorcontrib>Mendicino, Francesco</creatorcontrib><creatorcontrib>Lucia, Eugenio</creatorcontrib><creatorcontrib>Bossio, Sabrina</creatorcontrib><creatorcontrib>Recchia, Anna Grazia</creatorcontrib><creatorcontrib>Moia, Riccardo</creatorcontrib><creatorcontrib>Pietrasanta, Daniela</creatorcontrib><creatorcontrib>Loseto, Giacomo</creatorcontrib><creatorcontrib>Consoli, Ugo</creatorcontrib><creatorcontrib>Scortechini, Ilaria</creatorcontrib><creatorcontrib>Rossi, Francesca Maria</creatorcontrib><creatorcontrib>Zucchetto, Antonella</creatorcontrib><creatorcontrib>Al-Janazreh, Hamdi</creatorcontrib><creatorcontrib>Vitale, Candida</creatorcontrib><creatorcontrib>Tripepi, Giovanni</creatorcontrib><creatorcontrib>D’Arrigo, Graziella</creatorcontrib><creatorcontrib>Angeletti, Ilaria</creatorcontrib><creatorcontrib>Bomben, Riccardo</creatorcontrib><creatorcontrib>Neri, Antonino</creatorcontrib><creatorcontrib>Cutrona, Giovanna</creatorcontrib><creatorcontrib>Fronza, Gilberto</creatorcontrib><creatorcontrib>Di Raimondo, Francesco</creatorcontrib><creatorcontrib>Gaidano, Gianluca</creatorcontrib><creatorcontrib>Cuneo, Antonio</creatorcontrib><creatorcontrib>Foà, Robin</creatorcontrib><creatorcontrib>Ferrarini, Manlio</creatorcontrib><creatorcontrib>Trentin, Livio</creatorcontrib><creatorcontrib>Gattei, Valter</creatorcontrib><creatorcontrib>Morabito, Fortunato</creatorcontrib><title>Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab</title><title>Blood cancer journal (New York)</title><addtitle>Blood Cancer J</addtitle><addtitle>Blood Cancer J</addtitle><subject>692/699/1541/1990/283/1895</subject><subject>692/699/1541/1990/291/1621/1915</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Correspondence</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - mortality</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Oncology</subject><subject>Purines - administration & dosage</subject><subject>Quinazolinones - administration & dosage</subject><subject>Rituximab - administration & dosage</subject><subject>Survival Rate</subject><subject>Targeted cancer therapy</subject><issn>2044-5385</issn><issn>2044-5385</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp9kcFuFSEUhonR2ObaF-jCkLipi7GHgRlgY2JuWjW5SZNWuyUMMC117nALzLXd-Q6-oU8it7et1YVsIDkf__nP-RHaJ_COABWHiREGooIaKgDaiIo-Q7s1MFY1VDTPn7x30F5KV1BO0xJJ5Eu0Q2tJhQS2i67P9eCtzj6MOPRY4zTFtV_roYo-fcPJhOjwwdnp2VvsRxzdoFfJ2cPo-qhNDvEWzxcLvCoCbswJ5-h0dhZ_9_kSe1vwwSff_frxM_o83fil7l6hF70ektu7v2fo6_HRl_mnanHy8fP8w6IyjLNcWTCiNZwIMLaTvKtrJmUrW9py2UkA1jkBLXWOiJ5SKi3tTUO4JpxZJkhPZ-j9Vnc1dUtnTfEX9aBWsZiItypor_6ujP5SXYS14kwy0UAROLgXiOF6cimrpU_GDYMeXZiSqhmjgkso3WfozT_oVZjiWMbbULWglDdNoeotZWJIqazw0QwBtQlVbUNVJVR1F6raSL9-Osbjl4cIC0C3QCql8cLFP73_I_sb47GuVA</recordid><startdate>20200916</startdate><enddate>20200916</enddate><creator>Gentile, Massimo</creator><creator>Martino, Enrica Antonia</creator><creator>Visentin, Andrea</creator><creator>Coscia, Marta</creator><creator>Reda, Gianluigi</creator><creator>Sportoletti, Paolo</creator><creator>Mauro, Francesca Romana</creator><creator>Laurenti, Luca</creator><creator>Varettoni, Marzia</creator><creator>Murru, Roberta</creator><creator>Chiarenza, Annalisa</creator><creator>Vigna, Ernesto</creator><creator>Mendicino, Francesco</creator><creator>Lucia, Eugenio</creator><creator>Bossio, Sabrina</creator><creator>Recchia, Anna Grazia</creator><creator>Moia, Riccardo</creator><creator>Pietrasanta, Daniela</creator><creator>Loseto, Giacomo</creator><creator>Consoli, Ugo</creator><creator>Scortechini, Ilaria</creator><creator>Rossi, Francesca Maria</creator><creator>Zucchetto, Antonella</creator><creator>Al-Janazreh, Hamdi</creator><creator>Vitale, Candida</creator><creator>Tripepi, Giovanni</creator><creator>D’Arrigo, Graziella</creator><creator>Angeletti, Ilaria</creator><creator>Bomben, Riccardo</creator><creator>Neri, Antonino</creator><creator>Cutrona, Giovanna</creator><creator>Fronza, Gilberto</creator><creator>Di Raimondo, Francesco</creator><creator>Gaidano, Gianluca</creator><creator>Cuneo, Antonio</creator><creator>Foà, Robin</creator><creator>Ferrarini, Manlio</creator><creator>Trentin, Livio</creator><creator>Gattei, Valter</creator><creator>Morabito, Fortunato</creator><general>Nature Publishing Group UK</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5933-9680</orcidid><orcidid>https://orcid.org/0000-0001-9047-5912</orcidid><orcidid>https://orcid.org/0000-0002-3335-1101</orcidid><orcidid>https://orcid.org/0000-0002-2592-8724</orcidid><orcidid>https://orcid.org/0000-0003-1222-6149</orcidid><orcidid>https://orcid.org/0000-0003-3722-553X</orcidid><orcidid>https://orcid.org/0000-0002-5256-0726</orcidid><orcidid>https://orcid.org/0000-0003-1831-7340</orcidid><orcidid>https://orcid.org/0000-0001-7393-1138</orcidid><orcidid>https://orcid.org/0000-0002-2585-7073</orcidid></search><sort><creationdate>20200916</creationdate><title>Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab</title><author>Gentile, Massimo ; Martino, Enrica Antonia ; Visentin, Andrea ; Coscia, Marta ; Reda, Gianluigi ; Sportoletti, Paolo ; Mauro, Francesca Romana ; Laurenti, Luca ; Varettoni, Marzia ; Murru, Roberta ; Chiarenza, Annalisa ; Vigna, Ernesto ; Mendicino, Francesco ; Lucia, Eugenio ; Bossio, Sabrina ; Recchia, Anna Grazia ; Moia, Riccardo ; Pietrasanta, Daniela ; Loseto, Giacomo ; Consoli, Ugo ; Scortechini, Ilaria ; Rossi, Francesca Maria ; Zucchetto, Antonella ; Al-Janazreh, Hamdi ; Vitale, Candida ; Tripepi, Giovanni ; D’Arrigo, Graziella ; Angeletti, Ilaria ; Bomben, Riccardo ; Neri, Antonino ; Cutrona, Giovanna ; Fronza, Gilberto ; Di Raimondo, Francesco ; Gaidano, Gianluca ; Cuneo, Antonio ; Foà, Robin ; Ferrarini, Manlio ; Trentin, Livio ; Gattei, Valter ; Morabito, Fortunato</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-d0c86c7180cdb97b224996963679b9004be8063ee18f3339d3fc517a174d481f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>692/699/1541/1990/283/1895</topic><topic>692/699/1541/1990/291/1621/1915</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Correspondence</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - mortality</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Oncology</topic><topic>Purines - administration & dosage</topic><topic>Quinazolinones - administration & dosage</topic><topic>Rituximab - administration & dosage</topic><topic>Survival Rate</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gentile, Massimo</creatorcontrib><creatorcontrib>Martino, Enrica Antonia</creatorcontrib><creatorcontrib>Visentin, Andrea</creatorcontrib><creatorcontrib>Coscia, Marta</creatorcontrib><creatorcontrib>Reda, Gianluigi</creatorcontrib><creatorcontrib>Sportoletti, Paolo</creatorcontrib><creatorcontrib>Mauro, Francesca Romana</creatorcontrib><creatorcontrib>Laurenti, Luca</creatorcontrib><creatorcontrib>Varettoni, Marzia</creatorcontrib><creatorcontrib>Murru, Roberta</creatorcontrib><creatorcontrib>Chiarenza, Annalisa</creatorcontrib><creatorcontrib>Vigna, Ernesto</creatorcontrib><creatorcontrib>Mendicino, Francesco</creatorcontrib><creatorcontrib>Lucia, Eugenio</creatorcontrib><creatorcontrib>Bossio, Sabrina</creatorcontrib><creatorcontrib>Recchia, Anna Grazia</creatorcontrib><creatorcontrib>Moia, Riccardo</creatorcontrib><creatorcontrib>Pietrasanta, Daniela</creatorcontrib><creatorcontrib>Loseto, Giacomo</creatorcontrib><creatorcontrib>Consoli, Ugo</creatorcontrib><creatorcontrib>Scortechini, Ilaria</creatorcontrib><creatorcontrib>Rossi, Francesca Maria</creatorcontrib><creatorcontrib>Zucchetto, Antonella</creatorcontrib><creatorcontrib>Al-Janazreh, Hamdi</creatorcontrib><creatorcontrib>Vitale, Candida</creatorcontrib><creatorcontrib>Tripepi, Giovanni</creatorcontrib><creatorcontrib>D’Arrigo, Graziella</creatorcontrib><creatorcontrib>Angeletti, Ilaria</creatorcontrib><creatorcontrib>Bomben, Riccardo</creatorcontrib><creatorcontrib>Neri, Antonino</creatorcontrib><creatorcontrib>Cutrona, Giovanna</creatorcontrib><creatorcontrib>Fronza, Gilberto</creatorcontrib><creatorcontrib>Di Raimondo, Francesco</creatorcontrib><creatorcontrib>Gaidano, Gianluca</creatorcontrib><creatorcontrib>Cuneo, Antonio</creatorcontrib><creatorcontrib>Foà, Robin</creatorcontrib><creatorcontrib>Ferrarini, Manlio</creatorcontrib><creatorcontrib>Trentin, Livio</creatorcontrib><creatorcontrib>Gattei, Valter</creatorcontrib><creatorcontrib>Morabito, Fortunato</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood cancer journal (New York)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gentile, Massimo</au><au>Martino, Enrica Antonia</au><au>Visentin, Andrea</au><au>Coscia, Marta</au><au>Reda, Gianluigi</au><au>Sportoletti, Paolo</au><au>Mauro, Francesca Romana</au><au>Laurenti, Luca</au><au>Varettoni, Marzia</au><au>Murru, Roberta</au><au>Chiarenza, Annalisa</au><au>Vigna, Ernesto</au><au>Mendicino, Francesco</au><au>Lucia, Eugenio</au><au>Bossio, Sabrina</au><au>Recchia, Anna Grazia</au><au>Moia, Riccardo</au><au>Pietrasanta, Daniela</au><au>Loseto, Giacomo</au><au>Consoli, Ugo</au><au>Scortechini, Ilaria</au><au>Rossi, Francesca Maria</au><au>Zucchetto, Antonella</au><au>Al-Janazreh, Hamdi</au><au>Vitale, Candida</au><au>Tripepi, Giovanni</au><au>D’Arrigo, Graziella</au><au>Angeletti, Ilaria</au><au>Bomben, Riccardo</au><au>Neri, Antonino</au><au>Cutrona, Giovanna</au><au>Fronza, Gilberto</au><au>Di Raimondo, Francesco</au><au>Gaidano, Gianluca</au><au>Cuneo, Antonio</au><au>Foà, Robin</au><au>Ferrarini, Manlio</au><au>Trentin, Livio</au><au>Gattei, Valter</au><au>Morabito, Fortunato</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab</atitle><jtitle>Blood cancer journal (New York)</jtitle><stitle>Blood Cancer J</stitle><addtitle>Blood Cancer J</addtitle><date>2020-09-16</date><risdate>2020</risdate><volume>10</volume><issue>9</issue><spage>92</spage><pages>92-</pages><artnum>92</artnum><issn>2044-5385</issn><eissn>2044-5385</eissn><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32938904</pmid><doi>10.1038/s41408-020-00358-3</doi><orcidid>https://orcid.org/0000-0001-5933-9680</orcidid><orcidid>https://orcid.org/0000-0001-9047-5912</orcidid><orcidid>https://orcid.org/0000-0002-3335-1101</orcidid><orcidid>https://orcid.org/0000-0002-2592-8724</orcidid><orcidid>https://orcid.org/0000-0003-1222-6149</orcidid><orcidid>https://orcid.org/0000-0003-3722-553X</orcidid><orcidid>https://orcid.org/0000-0002-5256-0726</orcidid><orcidid>https://orcid.org/0000-0003-1831-7340</orcidid><orcidid>https://orcid.org/0000-0001-7393-1138</orcidid><orcidid>https://orcid.org/0000-0002-2585-7073</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2044-5385 |
| ispartof | Blood cancer journal (New York), 2020-09, Vol.10 (9), p.92, Article 92 |
| issn | 2044-5385 2044-5385 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7494850 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Springer Nature OA Free Journals; Nature Free; PubMed Central |
| subjects | 692/699/1541/1990/283/1895 692/699/1541/1990/291/1621/1915 Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - administration & dosage Biomedical and Life Sciences Biomedicine Cancer Research Correspondence Disease-Free Survival Female Hematology Humans Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - mortality Male Middle Aged Monoclonal antibodies Oncology Purines - administration & dosage Quinazolinones - administration & dosage Rituximab - administration & dosage Survival Rate Targeted cancer therapy |
| title | Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T16%3A36%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Validation%20of%20a%20survival-risk%20score%20(SRS)%20in%20relapsed/refractory%20CLL%20patients%20treated%20with%20idelalisib%E2%80%93rituximab&rft.jtitle=Blood%20cancer%20journal%20(New%20York)&rft.au=Gentile,%20Massimo&rft.date=2020-09-16&rft.volume=10&rft.issue=9&rft.spage=92&rft.pages=92-&rft.artnum=92&rft.issn=2044-5385&rft.eissn=2044-5385&rft_id=info:doi/10.1038/s41408-020-00358-3&rft_dat=%3Cproquest_pubme%3E2443879033%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2442833755&rft_id=info:pmid/32938904&rfr_iscdi=true |